{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:57Z","timestamp":1794047457746,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with heterogeneous presentations ranging from moderate constitutional symptoms to life-threatening multiorgan system involvement. There are vastly different clinical subtypes, with some patients demonstrating thrombocytopenia, anasarca, fever\/elevated C-reactive protein, reticulin fibrosis\/renal failure, and organomegaly (TAFRO) and others having milder\/more moderate symptoms with potential for severe disease (not otherwise specified, NOS). Due to its rarity and heterogeneity, the natural history and long-term burden of iMCD are poorly understood. We investigated real-world medical data from ACCELERATE, a large natural history registry of patients with Castleman disease, to better characterize the long-term disease burden experienced by these patients. We found that iMCD-TAFRO patients face a significant hospitalization burden, requiring more time in the hospital than iMCDNOS patients during the year surrounding diagnosis (median [interquartile range]: 36 [18-61] days vs. 0 [0-4] days; P&lt;0.001). In addition, we found life-sustaining interventions, such as mechanical ventilation (17%) and dialysis (27%), were required among iMCD patients, predominantly those with iMCD-TAFRO. iMCD-NOS patients, however, spent a significantly greater proportion of time following disease onset in a state of disease flare (median 52.3% vs. 18.9%; P=0.004). Lastly, we observed severe iMCD-related morbidities, such as acute renal failure, sepsis and pneumonia, among others, arising after iMCD diagnosis, impairing the patients\u2019 quality of life. These data demonstrate a substantial disease burden experienced by iMCD patients and emphasize the importance of ongoing research into iMCD to aid disease control.<\/jats:p>","DOI":"10.3324\/haematol.2023.283603","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:26:22Z","timestamp":1704943582000},"page":"2196-2206","source":"Crossref","is-referenced-by-count":12,"title":["Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease"],"prefix":"10.3324","volume":"109","author":[{"given":"Mateo Sarmiento","family":"Bustamante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brandstadter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Srkalovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Mango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"63392","doi-asserted-by":"crossref","unstructured":"Beck JT, Hsu SM, Wijdenes J. Brief report: alleviation of systemic manifestations of Castleman\u2019s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994; 330(9):602-605.","DOI":"10.1056\/NEJM199403033300904"},{"key":"63393","doi-asserted-by":"crossref","unstructured":"Yoshizaki K, Matsuda T, Nishimoto N. Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease. Blood. 1989; 74(4):1360-1367.","DOI":"10.1182\/blood.V74.4.1360.bloodjournal7441360"},{"key":"63394","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Langan RA, Japp AS. Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockaderefractory idiopathic multicentric Castleman disease. J Clin Invest. 2019; 129(10):4451-4463.","DOI":"10.1172\/JCI126091"},{"key":"63395","doi-asserted-by":"crossref","unstructured":"Arenas DJ, Floess K, Kobrin D. Increased mTOR activation in idiopathic multicentric Castleman disease. Blood. 2020; 135(19):1673-1684.","DOI":"10.1182\/blood.2019002792"},{"key":"63396","doi-asserted-by":"crossref","unstructured":"Pierson SK, Shenoy S, Oromendia AB. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021; 5(17):3445-3456.","DOI":"10.1182\/bloodadvances.2020004016"},{"key":"63397","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020; 383(23):2255-2273.","DOI":"10.1056\/NEJMra2026131"},{"key":"63398","doi-asserted-by":"crossref","unstructured":"Nishimura Y, Fajgenbaum DC, Pierson SK. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol. 2021; 96(10):1241-1252.","DOI":"10.1002\/ajh.26292"},{"key":"63399","doi-asserted-by":"crossref","unstructured":"Takeuchi K. Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980. J Clin Exp Hematop. 2022; 62(2):79-84.","DOI":"10.3960\/jslrt.22011"},{"key":"63400","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022; 6(2):359-367.","DOI":"10.1182\/bloodadvances.2021004441"},{"key":"63401","doi-asserted-by":"crossref","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017; 129(12):1646-1657.","DOI":"10.1182\/blood-2016-10-746933"},{"key":"63402","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Armitage JO, Loe MJ. The clinical spectrum of Castleman\u2019s disease. Am J Hematol. 2012; 87(11):997-1002.","DOI":"10.1002\/ajh.23291"},{"key":"63403","doi-asserted-by":"crossref","unstructured":"Cohen AB, Swaminathan A, Wang XL. Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease. J Clin Oncol. 2021; 39(15 suppl):7048.","DOI":"10.1200\/JCO.2021.39.15_suppl.7048"},{"key":"63404","doi-asserted-by":"crossref","unstructured":"Zhang L, Dong YJ, Peng HL. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. Lancet Reg Health West Pac. 2023; 34:100720.","DOI":"10.1016\/j.lanwpc.2023.100720"},{"key":"63405","doi-asserted-by":"crossref","unstructured":"van Rhee F, Wong RS, Munshi N. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014; 15(9):966-974.","DOI":"10.1016\/S1470-2045(14)70319-5"},{"key":"63406","doi-asserted-by":"crossref","unstructured":"van Rhee F, Voorhees P, Dispenzieri A. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018; 132(20):2115-2124.","DOI":"10.1182\/blood-2018-07-862334"},{"key":"63407","doi-asserted-by":"crossref","unstructured":"Nishimoto N, Kanakura Y, Aozasa K. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106(8):2627-2632.","DOI":"10.1182\/blood-2004-12-4602"},{"key":"63408","doi-asserted-by":"crossref","unstructured":"Mukherjee S, Kanhai K, Kauffman D. Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis. Leukemia. 2022; 36(10):2539-2543.","DOI":"10.1038\/s41375-022-01690-2"},{"key":"63409","doi-asserted-by":"crossref","unstructured":"Pierson SK, Khor JS, Ziglar J. ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder. Cell Rep Med. 2020; 1(9):100158.","DOI":"10.1016\/j.xcrm.2020.100158"},{"key":"63410","unstructured":"CDC. Hospital utilization (in non-Federal short-stay hospitals). 2018."},{"key":"63411","unstructured":"NHIS. About the National Health Interview Survey. 2019."},{"key":"63412","doi-asserted-by":"crossref","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021; 30(3):803-816.","DOI":"10.1007\/s11136-020-02650-y"},{"key":"63413","unstructured":"Owens PL, Liang L, Barrett ML, Fingar KR. Comorbidities associated with adult inpatient stays, 2019. Healthcare Cost and Utilization Project (HCUP) statistical briefs. 2006."},{"key":"63414","doi-asserted-by":"crossref","unstructured":"Liu AY, Nabel CS, Finkelman BS. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol. 2016; 3(4):e163-175.","DOI":"10.1016\/S2352-3026(16)00006-5"},{"key":"63415","doi-asserted-by":"crossref","unstructured":"Payera E, Zofia M, Zsofia S. Diagnostic and therapeutic difficulties in diffuse large B-cell lymphoma arising from HHV8 positive Castleman disease. J Hematol. 2012; 1(2):65-69.","DOI":"10.4021\/jh27w"},{"key":"63416","doi-asserted-by":"crossref","unstructured":"Sukswai N, Lyapichev K, Medeiros LJ, Khoury JD. Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. Clin Case Rep. 2019; 7(3):587-588.","DOI":"10.1002\/ccr3.2015"},{"key":"63417","doi-asserted-by":"crossref","unstructured":"Whooley M, Keirns D, Wu XX, Luker A, Silberstein PT, Hsia B. Diffuse large B-cell lymphoma in HHV8+ multicentric Castleman disease: a national analysis of demographic features. J Clin Oncol. 2023; 41(16 suppl):e19535.","DOI":"10.1200\/JCO.2023.41.16_suppl.e19535"},{"key":"63418","doi-asserted-by":"crossref","unstructured":"Nishikori A, Nishimura MF, Nishimura Y. Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric Castleman disease. Int J Mol Sci. 2022; 23(18):10301.","DOI":"10.3390\/ijms231810301"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283603\/76491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283603\/77189","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11401\/76491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:31Z","timestamp":1794045931000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283603","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}